Novel 1,2-dihydroquinazolin-2-ones: Design, synthesis, and biological evaluation against Trypanosoma brucei
作者:ThanhTruc Pham、Madeline Walden、Christopher Butler、Rosario Diaz-Gonzalez、Guiomar Pérez-Moreno、Gloria Ceballos-Pérez、Veronica Gomez-Pérez、Raquel García-Hernández、Henry Zecca、Emma Krakoff、Brian Kopec、Ogar Ichire、Caden Mackenzie、Marika Pitot、Luis Miguel Ruiz、Francisco Gamarro、Dolores González-Pacanowska、Miguel Navarro、Amy B. Dounay
DOI:10.1016/j.bmcl.2017.07.032
日期:2017.8
published report of the high-throughput screen of >42,000 kinase inhibitors from GlaxoSmithKline against T. brucei identified 797 potent and selective hits. From this rich data set, we selected NEU-0001101 (1) for hit-to-lead optimization. Through our preliminary compound synthesis and SAR studies, we have confirmed the previously reported activity of 1 in a T. brucei cell proliferation assay and have identified
2014年,已发表的报告对葛兰素史克公司的布鲁氏杆菌进行了高通量筛选,筛选了> 42,000种激酶抑制剂,鉴定出797种有效和选择性的药物。从这个丰富的数据集中,我们选择了NEU-0001101(1)进行潜在客户优化。通过我们的初步化合物合成和SAR的研究中,我们已经证实了先前报道的活动1在锥虫细胞增殖试验,并已确定替代群体,以取代吡啶环1。相对于1,吡唑24在效能和亲脂性上均得到了改善,同时还显示出良好的体外代谢稳定性。特区于图24为进一步优化用于抗锥虫药物发现的新型支架提供了新的方向。